Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1600 participants
INTERVENTIONAL
2007-09-30
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Minnesota Heart Health Program
NCT00005150
Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
NCT02382731
Patient-reported Outcomes After Percutaneous Coronary Intervention
NCT03810612
Enhancing Recovery in Coronary Heart Disease (ENRICHD) Patients
NCT00000557
Prevention of Early Readmission in Elderly Congestive Heart Failure Patients
NCT00000475
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multifactorial intervention
Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
smoking cessation
NRT and varenicline
betablocker, diuretics, ACEI, ARB,
blood pressure control according to ESC guidelines
statins, ezetimibe
Cholesterol reduction according to ESC guidelines
training
daily walking
influenza vaccine
vaccine (FLuarix, Influvac etc)
metformin, glimepiride, insulin
s.glucose control according to ESC guidelines
weight reduction
diet tips
Control
no intervention
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
smoking cessation
NRT and varenicline
betablocker, diuretics, ACEI, ARB,
blood pressure control according to ESC guidelines
statins, ezetimibe
Cholesterol reduction according to ESC guidelines
training
daily walking
influenza vaccine
vaccine (FLuarix, Influvac etc)
metformin, glimepiride, insulin
s.glucose control according to ESC guidelines
weight reduction
diet tips
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnant
* critical illness
* drug abuse
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oslo University Hospital
OTHER
Sorlandet Hospital HF
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sissel Ledang
Sorlandet Hospital HF
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Serena Tonstad, dr.med.
Role: STUDY_CHAIR
Ullevaal University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sorlandet Hospital
Arendal, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kaldal A, Tonstad S, Jortveit J. Self-reported smoking status and exhaled carbon monoxide in secondary preventive follow-up after coronary heart events: Do our patients tell the truth? Tob Prev Cessat. 2024 Sep 25;10. doi: 10.18332/tpc/191843. eCollection 2024.
Kaldal A, Tonstad S, Jortveit J. Sex differences in secondary preventive follow-up after coronary heart events. BMC Cardiovasc Disord. 2023 Sep 14;23(1):459. doi: 10.1186/s12872-023-03483-6.
Kaldal A, Tonstad S, Jortveit J. Association of Troponin T measurements with long-term outcomes in patients with coronary artery disease participating in a secondary prevention trial. BMC Cardiovasc Disord. 2023 Apr 28;23(1):210. doi: 10.1186/s12872-023-03249-0.
Kaldal A, Tonstad S, Jortveit J. Long-term hospital-based secondary prevention of coronary artery disease: a randomized controlled trial. BMC Cardiovasc Disord. 2021 Dec 16;21(1):600. doi: 10.1186/s12872-021-02426-3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-07041a (REK)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.